Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show
Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also highlighted that adding onvansertib to a standard Zytiga (by Janssen Biotech) and prednisone combination  led to treatment responses in patients carrying markers associated with resistance to Zytiga and other androgen receptor signaling (ARS) inhibitors. “Observing efficacy in patients that have tumors exhibiting known mechanisms of resistance to ARS inhibitor, Zytiga, suggests that onvansertib’s activity could extend to overcoming resistance to other ARS inhibitors, such as Xtandi and Erleada,” Mark Erlander, MD, Trovagene’s chief scientific officer, said in a press release. A poster with the data, “A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC),” was presented  at the 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held Feb. 13-15 in San Francisco. Onvansertib is an oral investigational therapy that blocks the activity of PLK1, an enzyme found at higher levels in multiple cancers and that plays a key role in tumor growth and spread (metastases). By suppressing PLK1, onvansertib is designed to stop cancer cells from proliferating, eventually leading to their death. Preclinical data suggested that onvansertib significantly boosts the efficacy of Zytiga in animal models of mCRPC. Trovagene launched a Phase 2 clinical trial (NCT03414034) to evaluate whether adding onvansertib to the standard Zytiga combination could halt cancer progression and extend s
Subscribe or to access all post and page content.